Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ProLectin-F
- Development stage
- Preclinical
- Lead developer
- BioXyTran
- Administration
- Intravenous
01
Overview
ProLectin-F is an intravenous (IV) polysaccharide-based galectin antagonist developed by BioXyTran. It is specifically designed to treat lung fibrosis resulting from ventilator use in COVID-19 patients. The drug works by targeting the galectin fold located on the N-terminal domain (NTD) of the SARS-CoV-2 spike protein, as well as blocking galectin-driven pathways involved in organ damage and fibrotic processes. Unlike other variants in the ProLectin platform (such as ProLectin-M for early-stage COVID-19), ProLectin-F is intended for use after the virus has been eliminated to address long-term respiratory complications and organ damage.
- Brand names
- ProLectin-F
02
Targets
LGALS3 (Galectin-3)
Beyond the preview
Go deeper on ProLectin-F.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ProLectin-F.